Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category ... discuss integrated evidence plans, data sharing optimization ...

Both deputy directors at the key FDA center that oversees regulation of cancer drugs plan on leaving the agency ...

The anticipation surrounding dose optimization data for Pfizer's obesity treatment ... due to the study's structure and disclosure plans. With a solid financial health score of "GOOD" from ...

In vaccines, Pfizer plans to start a Phase 3 study for PCV ... study is critical for Pfizer’s entry into the lucrative obesity market. It is still in progress, with data expected in Q1-CY25.

Pfizer and partner ... loss of 25%. NVO plans to file regulatory applications seeking approval for CagriSema in the first quarter of 2026. Roche Buys Rights to Obesity Drug from Zealand Pharma ...

In his first public comments, Pfizer’s new innovation chief — once a Wall Street analyst skeptical of the company — said he was confident in the company’s obesity plans and shed light on ...